Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | N/A | Complete | ||
| NA | icatibant | Hereditary Angioedema | Active | |||
| TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
| TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
| N/A | imiquimod | Gynecological cancers | Withdrawn | |||
| TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
| Padcev | enfortumab vedotin | Metastatic urothelial cancer | Pending | |||
| Venclexta | venetoclax | Chronic lymphocytic leukemia (CLL). | Pending | |||
| Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | |||
| Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn |
Last Updated : May 15, 2024